Academic Journal
Use and availability of anti-RhD immunoglobulin in Colombia following the 2024 national shortage.
| Τίτλος: | Use and availability of anti-RhD immunoglobulin in Colombia following the 2024 national shortage. |
|---|---|
| Συγγραφείς: | Barake-Ramos M; Applied Biomedical Sciences Research Group UR-BIOMED, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Castillo-Guerrero DA; Applied Biomedical Sciences Research Group UR-BIOMED, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Beltrán-Cardona I; Applied Biomedical Sciences Research Group UR-BIOMED, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bautista-Manrique OD; Applied Biomedical Sciences Research Group UR-BIOMED, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Parra-Galvis C; Applied Biomedical Sciences Research Group UR-BIOMED, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., García-Otálora MA; Applied Biomedical Sciences Research Group UR-BIOMED, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia. |
| Πηγή: | Vox sanguinis [Vox Sang] 2026 Jul; Vol. 121 (7), pp. 1076-1081. Date of Electronic Publication: 2026 Mar 12. |
| Τύπος έκδοσης: | Journal Article; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Blackwell Science Country of Publication: England NLM ID: 0413606 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0410 (Electronic) Linking ISSN: 00429007 NLM ISO Abbreviation: Vox Sang Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2001- : Oxford, UK : Blackwell Science Original Publication: Basel : Karger |
| Ιατρικοί όροι (MeSH): | Blood Group Incompatibility*/drug therapy , Blood Group Incompatibility*/immunology , Pregnancy Complications*/drug therapy , Pregnancy Complications*/immunology , Rho(D) Immune Globulin*/therapeutic use , Immunologic Factors*/supply & distribution , Erythroblastosis, Fetal*/prevention & control, Obstetrics/statistics & numerical data ; Colombia ; Cross-Sectional Studies ; Humans ; Female ; Pregnancy |
| Περίληψη: | Background and Objectives: In March 2024, the Colombian National Food and Drug Surveillance Institute declared a shortage of anti-RhD immunoglobulin, a critical product for preventing haemolytic disease of the foetus and newborn (HDFN) in RhD-negative women carrying RhD-positive foetuses. The aim of this work was to analyse the impact of this shortage on obstetric institutions, transfusion services and prophylactic management of the RhD-negative pregnant population. Materials and Methods: A descriptive, cross-sectional study was conducted using an online survey distributed between December 2024 and February 2025. Data were analysed according to region and experience with shortages. Results: Twenty-seven institutions (17.9%) providing obstetric and transfusion services completed the survey. Most respondents (88.9%) represented obstetric services, followed by transfusion medicine (7.4%) and clinical pharmacy (3.7%). In 92.6% of institutions, physicians prescribed anti-RhD immunoglobulin. Shortages were reported by 22.2% (n = 6) of institutions. Prophylaxis was administered during weeks 28-40 in 51.9% (n = 14) and during weeks 14-27 in 22.2% (n = 6), while one reported both periods. Anti-D administration was reported postpartum in 44.4% of cases, following abortion in 29.6%, after foetal haemorrhage in 7.4%, after trauma in 3.7% and once at the physician's discretion. Conclusion: Although some institutions reported shortages of anti-RhD immunoglobulin (particularly in the Andine region), these did not lead to changes in clinical indications, and prophylactic use during late pregnancy and the postpartum period remains the predominant practice nationwide. (© 2026 International Society of Blood Transfusion.) |
| References: | Levine P, Stetson R. An unusual case of intra‐group agglutination. JAMA. 1939;113:126–127. Race RR, Sanger R. Fisher's contribution to Rh. Vox Sang. 1982;43:354–356. Contreras M, Kumpel B, Olovnikova N. Anti‐D prophylaxis should protect all newborns from haemolytic disease, regardless of their country of residence. Vox Sang. 2024;119:1221–1222. Benavides‐Serralde JA, Buitrago‐Leal M, Molina‐Giraldo S, Benavides‐Calvache JP, Rivera‐Tobar J, López‐Rodríguez MJ, et al. Consenso colombiano de diagnóstico, prevención y manejo de la enfermedad Rh. Rev Colomb Obstet Ginecol. 2024;75:4142. Agencia Nacional de Referencia Regional. Dirección de medicamentos y productos biológicos. Listado de Medicamentos Vitales No Disponibles. 2024. Available from: https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/medicamentos-vitales-no-disponibles. Last accessed 27 Oct 2025. Tobian AAR, BenAvram D. Association bulletin #24–02. 2024. Available from: https://www.aabb.org/docs/default-source/default-document-library/resources/association-bulletins/ab24-02.pdf. Last accessed 27 Oct 2025. O'Brien K, Abels E, Bakhtary S, George M, Stephens L, Lu W. A survey on the use of Rh immune globulin during a nationwide shortage. Transfusion. 2025;65:2286–2292. Instituto Nacional de Salud. Directorio de bancos de sangre en Colombia. Available from: https://www.ins.gov.co/BibliotecaDigital/directorio‐bancos‐de‐sangre‐colombia.pdf. Last accessed 9 Jan 2025. Instituto Nacional de Salud. Directorio de Coordinadores Departamentales de Red Nacional de Bancos de Sangre, Colombia. Available from: https://www.ins.gov.co/BibliotecaDigital/directorio‐coordinaciones‐departamentales‐y‐distritales‐red‐de‐sangre‐2024.pdf. Last accessed 9 Jan 2025. Bermúdez‐Forero M, Delgado‐López D, Anzola‐Samudio D, Palomino F, Garcia‐Otalora M. Role of disruptions in O RhD negative donations in Colombia on increasing maternal mortality ratio from haemorrhage. Transfus Med. 2024;34:142–153. Blood type frequencies by country including the Rh factor. Rhesus negative. 2012. Available from: https://www.rhesusnegative.net/themission/bloodtypefrequencies/. Last accessed 26 Oct 2025. Grupo Coordinación Red Nacional Bancos de Sangre y Servicios de Transfusión. Instituto Nacional de Salud. Informe Nacional Bancos de Sangre 2023. 2024. Available from: https://www.ins.gov.co/BibliotecaDigital/informe-nacional-actividad-transfusional-2023.pdf. Last accessed 26 Oct 2025. MINSALUD‐IETS. Guía de práctica clínica basada en la evidencia para el uso de componentes sanguíneos (adopción). 1st ed. Bogotá: MINSALUD‐IETS; 2016. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc‐completa‐componentes‐sanguineos.pdf. Last accessed 24 Feb 2026. Serna Trejos JS, Castro Galvis CA, Bermúdez Moyano SG, Rodríguez Fonseca LC, Diaz Beltrán JC, Mantilla Melo DA, et al. Caracterización de la respuesta al tratamiento con inmunoglobulina ANTI‐D en pacientes con trombocitopenia inmune primaria en un centro de salud colombiano de alta complejidad. Rev Colomb Hematol Oncol. 2025;12:26–39. National Administrative Department of Statistics – DANE. National population series by area, sex, and age for 2018–2070. 2023: births and non‐fetal deaths: final figures for 2024 and 2025 (January–July). 2023. National Administrative Department of Statistics. 2025. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion. Last accessed 26 Oct 2025. |
| Contributed Indexing: | Keywords: Colombia; RhD alloimmunization; anti‐D immunoglobulin; drug shortages; haemolytic disease of the foetus and the newborn; immunoprophylaxis |
| Substance Nomenclature: | 0 (Rho(D) Immune Globulin) 0 (Immunologic Factors) |
| Entry Date(s): | Date Created: 20260313 Date Completed: 20260714 Latest Revision: 20260726 |
| Update Code: | 20260726 |
| PubMed Central ID: | PMC13356984 |
| DOI: | 10.1111/vox.70250 |
| PMID: | 41820260 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1423-0410 |
|---|---|
| DOI: | 10.1111/vox.70250 |